[go: up one dir, main page]

ATE447844T1 - Neue immuneffektor-verbindungen - Google Patents

Neue immuneffektor-verbindungen

Info

Publication number
ATE447844T1
ATE447844T1 AT02723106T AT02723106T ATE447844T1 AT E447844 T1 ATE447844 T1 AT E447844T1 AT 02723106 T AT02723106 T AT 02723106T AT 02723106 T AT02723106 T AT 02723106T AT E447844 T1 ATE447844 T1 AT E447844T1
Authority
AT
Austria
Prior art keywords
compounds
immune effector
new immune
effector compounds
antigen
Prior art date
Application number
AT02723106T
Other languages
English (en)
Inventor
David Johnson
Jory Baldridge
Greg Sowell
Christopher Cluff
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Application granted granted Critical
Publication of ATE447844T1 publication Critical patent/ATE447844T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26Acyclic or carbocyclic radicals, substituted by hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549Sugars, nucleosides, nucleotides or nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
AT02723106T 2002-02-04 2002-02-04 Neue immuneffektor-verbindungen ATE447844T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2002/003580 WO2003065806A1 (en) 2002-02-04 2002-02-04 New immunoeffector compounds

Publications (1)

Publication Number Publication Date
ATE447844T1 true ATE447844T1 (de) 2009-11-15

Family

ID=27732075

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02723106T ATE447844T1 (de) 2002-02-04 2002-02-04 Neue immuneffektor-verbindungen

Country Status (19)

Country Link
EP (1) EP1482795B1 (de)
JP (1) JP2005516980A (de)
KR (1) KR100885008B1 (de)
CN (1) CN1301134C (de)
AT (1) ATE447844T1 (de)
AU (1) AU2002253909B2 (de)
BR (1) BR0215588A (de)
CA (1) CA2474398A1 (de)
CY (1) CY1109692T1 (de)
CZ (1) CZ2004862A3 (de)
DE (1) DE60234386D1 (de)
DK (1) DK1482795T3 (de)
ES (1) ES2336080T3 (de)
HU (1) HUP0500539A2 (de)
IL (1) IL163304A (de)
MX (1) MXPA04008559A (de)
NO (1) NO20043707L (de)
PT (1) PT1482795E (de)
WO (1) WO2003065806A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0402570A3 (en) * 2002-02-04 2006-02-28 Corixa Corp Seattle Prophylactic and therapeutic treatment of infectious and other diseases with aminoalkyl glucosaminide phosphate (cyclic a 6p) immunoeffector compounds
US6911434B2 (en) 2002-02-04 2005-06-28 Corixa Corporation Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
DK3017827T3 (en) 2005-12-22 2019-02-18 Glaxosmithkline Biologicals Sa Pneumococcal polysaccharide conjugate VACCINE
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
EP2392675A1 (de) 2006-06-02 2011-12-07 GlaxoSmithKline Biologicals S.A. Verfahren zur Indentifizierung des Ansprechens bzw. Nichtansprechens eines Patienten auf eine Immuntherapie basierend auf die Differentielle Expression vom Gen IFNG
CN101883583B (zh) 2007-06-26 2017-05-17 葛兰素史密丝克莱恩生物有限公司 含有肺炎链球菌荚膜多糖缀合物的疫苗
EA017879B1 (ru) 2007-09-17 2013-03-29 Онкометилом Сайенсиз Са Улучшенное определение экспрессии mage-a
AU2010225125A1 (en) 2009-03-17 2011-10-20 Glaxosmithkline Biologicals S.A. Improved detection of gene expression
GB0917457D0 (en) 2009-10-06 2009-11-18 Glaxosmithkline Biolog Sa Method
GB201101331D0 (en) 2011-01-26 2011-03-09 Glaxosmithkline Biolog Sa Compositions and uses
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
GB2599572B (en) * 2019-05-20 2023-09-20 Soligenix Inc Compositions and methods of manufacturing trivalent filovirus vaccines
BR112022000710A2 (pt) 2019-07-21 2022-03-22 Glaxosmithkline Biologicals Sa Vacina viral terapêutica
US20230234992A1 (en) 2020-06-05 2023-07-27 Glaxosmithkline Biologicals Sa Modified betacoronavirus spike proteins
EP4032547A1 (de) 2021-01-20 2022-07-27 GlaxoSmithKline Biologicals S.A. Hsv1 fce abgeleitete fragemente zur hsv therapie

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987237A (en) * 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
US5607698A (en) * 1988-08-04 1997-03-04 Ciba-Geigy Corporation Method of preserving ophthalmic solution and compositions therefor
US6113918A (en) * 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6013640A (en) 1998-08-21 2000-01-11 Ribi Immunochem Research, Inc. Phosphoglycolipid and methods for its use
US6699846B2 (en) 2000-03-17 2004-03-02 Corixa Corporation Mono- and disaccharides for the treatment of nitric oxide related disorders
ES2261453T3 (es) * 2000-08-04 2006-11-16 Corixa Corporation Nuevos compuestos inmunoefectores.
HUP0402570A3 (en) * 2002-02-04 2006-02-28 Corixa Corp Seattle Prophylactic and therapeutic treatment of infectious and other diseases with aminoalkyl glucosaminide phosphate (cyclic a 6p) immunoeffector compounds

Also Published As

Publication number Publication date
MXPA04008559A (es) 2004-12-06
EP1482795A4 (de) 2006-08-09
CY1109692T1 (el) 2014-08-13
HUP0500539A2 (en) 2006-09-28
EP1482795B1 (de) 2009-11-11
NO20043707L (no) 2004-09-03
CN1622754A (zh) 2005-06-01
AU2002253909B2 (en) 2008-06-05
ES2336080T3 (es) 2010-04-08
BR0215588A (pt) 2005-03-22
IL163304A (en) 2010-11-30
CA2474398A1 (en) 2003-08-14
WO2003065806A1 (en) 2003-08-14
CZ2004862A3 (cs) 2005-01-12
AU2002253909A1 (en) 2003-09-02
PT1482795E (pt) 2010-02-09
EP1482795A1 (de) 2004-12-08
KR100885008B1 (ko) 2009-02-20
CN1301134C (zh) 2007-02-21
DE60234386D1 (de) 2009-12-24
DK1482795T3 (da) 2010-02-01
JP2005516980A (ja) 2005-06-09
KR20040083433A (ko) 2004-10-01

Similar Documents

Publication Publication Date Title
ATE321063T1 (de) Neue immunoeffectorverbindungen
ATE447844T1 (de) Neue immuneffektor-verbindungen
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
TR200103018T2 (tr) İmmünostimülatör oligonükleotid ve saponin içeren katkı bileşikleri.
DE602004029904D1 (de) Neue tricyclische nukleoside oder nukleotide als therapeutische mittel
CY1112993T1 (el) Παραγοντες ειδικης δεσμευσης της αγγειοποιητινης-2 και της αγγειοποιητινης-1
NO20072526L (no) Halvfaste C-klasse immunstimulerende oligonukleotider
ATE455127T1 (de) Humane anti-humane cd3-bindungsmoleküle
BR0315161A (pt) Anticorpo isolado, polinicleotìdeo isolado, vetor, célula hospedeira, método de produzir um anticorpo, e, composição
IL195338A0 (en) Optimized fc variants and methods for their generation
NO20062146L (no) Nukleosidforbindelser for behandling av virusinfeksjoner
TW200512457A (en) Method of diagnosing SARS corona virus infection
ATE426412T1 (de) Adjuvante influenza-vakzine
NO20041917D0 (no) Spesifikke midler som binder humant angiopoietin-2
MXPA05014016A (es) Proteinas portadoras para vacunas.
EA200300464A1 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ
UA84284C2 (ru) Способы лечения, профилактики и диагностики инфекции helicobacter cerdo
TW200633719A (en) Glycoconjugate vaccines containing peptidoglycan
DE602004027251D1 (de) Herstellung von 1,3-diphenylprop-2-en-1-onderivaten
BRPI0417992A (pt) método para purificar fsh
NO20070351L (no) Materialer og fremgangsmater for forbedring av skalldyrhelse, -immunitet og -vekst
AP1729A (en) Single dose azithromycin for treating respiratory infections.
DE602004028592D1 (de) Gegen clostridium difficile gerichtete antikörper
WO2007002587A3 (en) Inhibitors of epstein barr virus nuclear antigen 1
ES2502366T3 (es) Inducción de inmunidad tumoral por variantes de proteína de unión a folato

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1482795

Country of ref document: EP